Kawanishi D T, Reid C L, Gonzales A, O'Rourke R A, Rahimtoola S H
Department of Medicine, LAC-USC Medical Center, University of Southern California School of Medicine 90033.
Circulation. 1989 Dec;80(6 Suppl):IV162-70.
We studied 14 patients to determine whether sustained-release diltiazem is a satisfactory long-term substitute for the combination of propranolol plus hydrochlorothiazide (HCTZ), control phase, in the treatment of systemic hypertension with coexisting chronic stable angina pectoris. All patients had either one- or two-vessel coronary disease and normal left ventricular systolic function. Measurements were made during the control phase and 4 and 8 weeks after substitution of sustained-release diltiazem. Only the sitting blood pressure was available before the control phase (pretreatment). Blood pressure and heart rate were measured with patients supine, sitting, and 5 minutes after standing. Cardiac output was measured in the supine position using a computerized Doppler system, and stroke volume, mean arterial pressure, and total systemic resistance were calculated. Symptom-limited modified Bruce protocol treadmill tests were performed to determine time to onset of 1 mm ST segment depression, time to termination of exercise, reason for cessation of exercise, and maximum rate-pressure product. The patients were initially receiving 160-240 mg/day of propranolol (40-60 mg q.i.d.) plus 25-50 mg/day of HCTZ and, subsequently, 12 of 14 had substitution with 240 mg/day (120 mg b.i.d.) of sustained-release diltiazem, and two received 360 mg/day with one of these patients also receiving 50 mg/day of HCTZ. These patients are a subset of a larger group of patients in whom the response of blood pressure alone has been previously reported. Diltiazem resulted in reduction of blood pressure equivalent to that with the propranolol plus HCTZ combination.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了14例患者,以确定缓释地尔硫䓬是否是普萘洛尔加氢氯噻嗪(HCTZ)联合用药(对照阶段)在治疗合并慢性稳定型心绞痛的系统性高血压时令人满意的长期替代药物。所有患者均患有单支或双支冠状动脉疾病且左心室收缩功能正常。在对照阶段以及替换为缓释地尔硫䓬后的4周和8周进行测量。对照阶段(预处理)前仅可获得坐位血压。在患者仰卧位、坐位以及站立5分钟后测量血压和心率。使用计算机化多普勒系统在仰卧位测量心输出量,并计算每搏输出量、平均动脉压和总全身阻力。进行症状限制的改良布鲁斯方案跑步机试验,以确定出现1毫米ST段压低的时间、运动终止时间、运动停止原因以及最大速率 - 压力乘积。患者最初接受160 - 240毫克/天的普萘洛尔(40 - 60毫克,每日4次)加25 - 50毫克/天的HCTZ,随后,14例中有12例替换为240毫克/天(120毫克,每日2次)的缓释地尔硫䓬,2例接受360毫克/天,其中1例患者还接受50毫克/天的HCTZ。这些患者是先前已报告仅血压反应的较大患者群体的一个子集。地尔硫䓬导致的血压降低与普萘洛尔加HCTZ联合用药相当。(摘要截短为250字)